India, Nov. 17 -- ProMIS Neurosciences Inc. (PMN), a clinical-stage biotechnology company, on Tuesday announced signing a license agreement with Ossianix Inc. for TXP1, a brain shuttling technology with potential applications in treating Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

TXP1 was built by Ossianix on a deimmunized, single-body scaffold with variable new antigen receptors (VNAR), thus shrinking its size to be much smaller than a conventional antibody. This permits TXP1 to pass the blood-brain-barrier and deliver the attached drug to a target brain tissue.

In preclinical studies on non-human primates, TXP1 increased delivery of a therapeutic antibody to the brain by more than 65-fold with no ...